Targeting TROP2 in Breast Cancer: How Experts are Integrating TROP2 ADCs into Clinical Practice

Get up to date on approved and emerging TROP-2–targeted antibody–drug conjugates in triple-negative and hormone receptor–positive advanced breast cancer with downloadable slides and an archived webcast from a live workshop developed for the oncology multidisciplinary care team.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.